We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App




Companies Collaborate on Nuclear Medicine Therapy for Neuroendocrine Tumors

By HospiMedica staff writers
Posted on 15 Nov 2007
Print article
Covidien, Ltd. (St. Louis, MO, USA) and BioSynthema, Inc. (St. Louis, MO, USA) have signed an agreement to develop and commercialize a nuclear medicine therapy for neuroendocrine cancer patients.

Under the terms of an exclusive license agreement, BioSynthema will gain access to specific Covidien proprietary peptide technology. The license will enable BioSynthema to use this technology in conjunction with its own technology and proprietary clinical research to further develop a new targeted-radionuclide therapy product. Under the terms of a separate agreement, Covidien will have exclusive marketing rights to the resulting cancer therapy technology.

"We are very pleased to be working with BioSynthema on this important technology,” said Steve Hanley, president of Covidien Imaging Solutions. "This project reflects Covidien's commitment to the future of nuclear medicine and to the development of new and unique radiolabeled products.”

The new technology utilizes a radiolabeled peptide that targets specific somatostatin receptors on neuroendocrine cancer cells. If approved, this drug candidate will add to Covidien's range of nuclear medicine oncology agents, including OctreoScan (kit for the preparation of indium In-111 pentetreotide), a molecular imaging agent that is indicated for the scintigraphic detection and localization of primary and metastatic neuroendocrine tumors bearing somatostatin receptors. The safety and effectiveness of OctreoScan imaging agent in pediatric patients have not been established, and use in patients with impaired renal function should be carefully considered.

Covidien Imaging Solutions is a provider of imaging products used by physicians to detect and diagnose various diseases. BioSynthema is a drug discovery and development company focusing on unique pharmaceuticals that target cell surface receptors overexpressed in cancer cells.

Using this technology, BioSynthema has collaborated with Eric Krenning, M.D., Ph.D., FRCP, and professor of nuclear medicine at the Erasmus Medical Centre (Rotterdam, The Netherlands), for more than five years on a clinical therapy study, which has enrolled over 600 patients. "I am very encouraged that Covidien and BioSynthema have agreed to cooperate in the development and commercialization of this product,” said Prof. Krenning.

"The incidence of neuroendocrine tumors is approximately 20,000 new cases per year in the U.S. and Europe,” said Jack Erion, Ph.D., president and CEO of BioSynthema. "If approved, this technology would provide a new therapeutic drug for those patients who currently have very limited treatment options.”

Under the terms of the agreements, BioSynthema will develop and manufacture the product and Covidien will be responsible for worldwide marketing, sales, and distribution. The companies plan to pursue marketing authorization in Europe and the United States initially.


Related Links:
Covidien
BioSynthema
Gold Member
12-Channel ECG
CM1200B
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Transcatheter Heart Valve
SAPIEN 3 Ultra
New
Computed Tomography System
Aquilion ONE / INSIGHT Edition

Print article

Channels

Surgical Techniques

view channel
Image: The new treatment combination for subdural hematoma reduces the risk of recurrence (Photo courtesy of Neurosurgery 85(6):801-807, December 2019)

Novel Combination of Surgery and Embolization for Subdural Hematoma Reduces Risk of Recurrence

Subdural hematomas, which occur when bleeding happens between the brain and its protective membrane due to trauma, are common in older adults. By 2030, chronic subdural hematomas are expected to become... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The acoustic pipette uses sound waves to test for biomarkers in blood (Photo courtesy of Patrick Campbell/CU Boulder)

Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour

Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.